Patent 8697662 was granted and assigned to Ptc Therapeutics, Inc. on April, 2014 by the United States Patent and Trademark Office.
Methods for treating Kaposi's sarcoma involving the administration of a compound that selectively inhibits pathological production of human VEGF are described. The compound can be administered as a single-agent therapy or in combination with one or more additional therapies to a human in need of such treatment.